AstraZeneca's vaccine will soon be approved in the EU.
But what distinguishes it from the active ingredient from Biontech?
in the UK
The European Union has ordered several
hundred million doses of
But what is the difference to the
In the past year, numerous companies
around the world
hard on a
vaccine against the coronavirus
, hoping to get the pandemic under control.
reported by echo24.de
first approved in Great Britain, followed by the USA, Canada and the European Union (EU).
AstraZeneca's vaccine has now also received approval in the UK *.
A release from the European Medicines Agency (EMA) is still
and, according to
probably take place in February at the earliest.
Months ago, the EU ordered
300 million doses of the vaccine
There is also an option for a further 100 million cans.
But what is the difference
between AstraZeneca and Biontech vaccines
Coronavirus vaccine: this is how AstraZeneca's active ingredient works
The approach to vaccine development is
for the two
vaccines against the coronavirus
According to the
Paul Ehrlich Institute (PEI) for vaccines and biomedical drugs,
new active ingredient
a so-called vector
A chimpanzee cold virus is used, which cannot reproduce in humans, as
In order for the virus to
, however, the gene must be modified in such a way that it contains the blueprint for the production of the Sars-CoV-2 spike protein.
This spike protein is responsible in the body for enabling the virus to multiply.
Coronavirus vaccine: AstraZeneca relies on best practice
In the body, this blueprint then gets into some body cells, which then begin to produce this spike protein.
Since the body's own immune system does not know this protein, it begins with the production of antibodies and T cells, which are then
supposed to protect against
So far, however, there are only a few
that use the vector method, but it is still considered to be tried and tested and effective.
In addition to the
vaccine against the coronavirus
, the active ingredient that protects against Ebola is also based on the vector process.
Vaccine against the coronavirus: Biontech relies on new mRNA process
meanwhile relies on an mRNA-based
In contrast to conventional vaccines, according to the Mainz-based company, these contain no viral proteins, "only the information that our own cells need to produce a virus characteristic that triggers the desired immune response".
AtraZenca's vaccine is already being vaccinated in the UK.
© Gareth Fuller / dpa
This mRNA is released in the body and uses "small, harmless fragments of the Covid 19 virus" to explain to the cells how they can "recognize and attack the virus".
The cells remember this information and thus ensure immunity against the
In addition, not only should the replication and spread in the body be prevented, but also transmission to other people.
Coronavirus vaccine: That's how effective the active ingredients from AstraZeneca and Biontech are
The mRNA vaccine - which Moderna and CureVac are also developing - from
has an effectiveness of around 95 percent after two vaccinations within three weeks.
protection of just around 70 percent in November 2020.
In the meantime, a team of researchers at Oxford University has found that
protection of around 90 percent is achieved
with two lower
two full doses
, however, the value was just 62 percent.
However, criticism has been
AstraZeneca's vaccine has
only been tested on subjects under the age of 55 and therefore no information is available about its effectiveness in seniors.
Oxford / Astra vaccine shows about 90% effectiveness in the best dosage (2 vaccinations).
Stored in refrigerators, billions of euros will be produced non-profit in 2021 and, in a study, avoided all difficult processes.
A sensational success.
Congratulations Oxford https://t.co/xkgKfHABkw
- Karl Lauterbach (@Karl_Lauterbach) November 23, 2020
Vaccine against the coronavirus: differentiate between AstraZeneca and Biontech in the overview
Vector vs. mRNA vaccine:
The British-Swedish company AstraZeneca uses
the vector method
for its vaccine against the
Biontech, on the other hand, has developed a
based on the mRNA.
Unlike the vector method, this has not yet been used in practice.
Both vaccines are highly effective at the correct dose, but must be administered twice.
The active ingredient from
achieves a protection of 90 percent, that of
protects about 95 percent against infection.
: Storage is one of the great advantages
of AstraZeneca's vaccine
Biontech active ingredient
must be stored at a temperature of -70 degrees, the vector
can be stored in the refrigerator.
Thus, it is also suitable for medical practices and a nationwide vaccination.
vaccine from AstraZeneca is
also significantly cheaper than the
Biontech competitor at
1.78 euros per dose
This costs around 12 euros per can.
higher costs are
probably related to the manufacturing process.
The side effects of the AstraZeneca vaccine * hardly differ from those of the active ingredient from Biontech *.
However, there were
several problems with allergic reactions *
the Mainz-based company.
echo24.de is part of the Ippen-Digital network
List of rubric lists: © John Cairns / University Of Oxford